Live Cell Monitoring of Phosphodiesterase Inhibition by Sulfonylurea Drugs
Biomolecules · 2024
DOI: 10.3390/biom14080985 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Filip Berisha und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of General and Interventional Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, 20246…. Hauptthemen laut MEDLINE: Sulfonylurea Compounds, Guanine Nucleotide Exchange Factors, Cyclic AMP. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Gertraud und Heinz Rose-Stiftung.
Abstract (Originalsprache)
Sulfonylureas (SUs) are a class of antidiabetic drugs widely used in the management of diabetes mellitus type 2. They promote insulin secretion by inhibiting the ATP-sensitive potassium channel in pancreatic β-cells. Recently, the exchange protein directly activated by cAMP (Epac) was identified as a new class of target proteins of SUs that might contribute to their antidiabetic effect, through the activation of the Ras-like guanosine triphosphatase Rap1, which has been controversially discussed. We used human embryonic kidney (HEK) 293 cells expressing genetic constructs of various Förster resonance energy transfer (FRET)-based biosensors containing different versions of Epac1 and Epac2 isoforms, alone or fused to different phosphodiesterases (PDEs), to monitor SU-induced conformational changes in Epac or direct PDE inhibition in real time. We show that SUs can both induce conformational changes in the Epac2 protein but not in Epac1, and directly inhibit the PDE3 and PDE4 families, thereby increasing cAMP levels in the direct vicinity of these PDEs. Furthermore, we demonstrate that the binding site of SUs in Epac2 is distinct from that of cAMP and is located between the amino acids E443 and E460. Using biochemical assays, we could also show that tolbutamide can inhibit PDE activity through an allosteric mechanism. Therefore, the cAMP-elevating capacity due to allosteric PDE inhibition in addition to direct Epac activation may contribute to the therapeutic effects of SU drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General and Interventional Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
- Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
- German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, 20246 Hamburg, Germany.
ORCID-Profile: Viacheslav O Nikolaev
Förderung
- the Gertraud und Heinz Rose-Stiftung
Zitieren
APA
Berisha, F., Blankenberg, S., & Nikolaev, V. O. (2024). Live Cell Monitoring of Phosphodiesterase Inhibition by Sulfonylurea Drugs. Biomolecules. https://doi.org/10.3390/biom14080985
Vancouver
Berisha F, Blankenberg S, Nikolaev VO. Live Cell Monitoring of Phosphodiesterase Inhibition by Sulfonylurea Drugs. Biomolecules. 2024. doi:10.3390/biom14080985
BibTeX
@article{Berisha2024,
author = {Berisha, Filip and Blankenberg, Stefan and Nikolaev, Viacheslav O},
title = {Live Cell Monitoring of Phosphodiesterase Inhibition by Sulfonylurea Drugs},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14080985}
}
EUVIMED